Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from CytomX Therapeutics ( (CTMX) ).
On August 13, 2025, CytomX Therapeutics announced an update on its CX-2051 Phase 1 study, detailing dose expansions and a treatment-related incident. Despite a Grade 5 acute kidney injury in a patient, the study continues with support from the Safety Review Committee, and a data update is expected by Q1 2026.
The most recent analyst rating on (CTMX) stock is a Buy with a $3.50 price target. To see the full list of analyst forecasts on CytomX Therapeutics stock, see the CTMX Stock Forecast page.
Spark’s Take on CTMX Stock
According to Spark, TipRanks’ AI Analyst, CTMX is a Neutral.
CytomX Therapeutics’ overall stock score reflects a mix of positive and negative factors. The company’s strong clinical progress and strategic financial moves are significant positives, but they are offset by financial instability and bearish technical indicators. The low P/E ratio suggests potential undervaluation, but solvency and liquidity risks remain a concern.
To see Spark’s full report on CTMX stock, click here.
More about CytomX Therapeutics
CytomX Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies. The company specializes in creating Probody therapeutics, which are designed to target cancer cells while minimizing damage to healthy tissue.
Average Trading Volume: 2,756,182
Technical Sentiment Signal: Hold
Current Market Cap: $306.7M
For detailed information about CTMX stock, go to TipRanks’ Stock Analysis page.